-
BMJ Clinical Evidence Aug 2007Diverticula (mucosal outpouching through the wall of the colon) affect over 5% of adults aged 40 years and older, but only 10-25% of affected people will develop... (Review)
Review
INTRODUCTION
Diverticula (mucosal outpouching through the wall of the colon) affect over 5% of adults aged 40 years and older, but only 10-25% of affected people will develop symptoms such as lower abdominal pain. Recurrent symptoms are common, and 5% of people with diverticula eventually develop complications such as perforation, obstruction, haemorrhage, fistulae, or abscesses.
METHODS AND OUTCOMES
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of: treatments for uncomplicated diverticular disease; treatments to prevent complications; and treatments for acute diverticulitis? We searched: Medline, Embase, The Cochrane Library and other important databases up to July 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS
We found 13 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS
In this systematic review we present information relating to the effectiveness and safety of the following interventions: antispasmodics, bran, elective surgery, increasing fibre intake, ispaghula husk, lactulose, medical treatment, mesalazine, methylcellulose, rifaximin, surgery.
Topics: Acute Disease; Diverticulitis; Diverticulitis, Colonic; Diverticulosis, Colonic; Diverticulum; Humans; Mesalamine
PubMed: 19454119
DOI: No ID Found -
Georgian Medical News Sep 2023The aim of this paper is to estimate Mesalazine or Mesalamine (MESA) in pharmaceuticals. The reversed-phase HPLC (RP-HPLC) results were used to evaluate the type of...
The aim of this paper is to estimate Mesalazine or Mesalamine (MESA) in pharmaceuticals. The reversed-phase HPLC (RP-HPLC) results were used to evaluate the type of Mesalazine. Chromatographic analysis was carried out using an HPLC-UV method along with an Ion Pac column (Arcus EP-C18; 5 m, 4.6 mm, 250 mm) and a mobile phase of acetonitrile: acetic acid: water, 40:40:20 (v/v/v) + 0.5 M potassium dihydrogen orthophosphate buffer at pH 3.3, at a flow rate of 1.0 ml/min. At 260 nm, UV detection was employed in the HPLC method. Exactness, precision, particularity, linearity, and affectability were all accepted for the technique. The (MESA) had a maintenance time of (3.17) minutes. The (MESA) alignment plots were over the target ranges of 1-5 g/L, R2 0.9998. The quantitation limit was 0.3613 g/ml, with a detection limit of 1.636 g/ml. The precision of the proposed procedure, which ranged from 98.0 percent to 100 percent, was determined through recovery experiments. The modern HPLC-UV approach was used to analyze generic drug products, and the planned technique's efficiency was confirmed. The study's findings show that precision, accuracy, and efficiency are all within reasonable limits, so there is no substantial difference between the values obtained using the proposed methodology and those obtained using the traditional method.
Topics: Chromatography, High Pressure Liquid; Mesalamine
PubMed: 37991958
DOI: No ID Found -
Alimentary Pharmacology & Therapeutics Nov 2022
Topics: Female; Fertilization; Humans; Mesalamine; Pregnancy; Pregnancy Complications
PubMed: 36221161
DOI: 10.1111/apt.17205 -
Gastroenterologia Y Hepatologia Apr 2015
Topics: Administration, Oral; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Humans; Male; Mesalamine; Middle Aged; Proctocolitis; Suppositories
PubMed: 25458543
DOI: 10.1016/j.gastrohep.2014.09.002 -
ANZ Journal of Surgery Oct 2015Acute diverticulitis (AD) is one of the most common acute admission diagnoses for general surgery, and its prevalence is increasing, in part due to the ageing... (Review)
Review
Acute diverticulitis (AD) is one of the most common acute admission diagnoses for general surgery, and its prevalence is increasing, in part due to the ageing population. Currently, most patients who present to a tertiary hospital are admitted for a period of treatment and observation. Simple, safe and cost-effective strategies for improving our current treatment of this condition will be invaluable in providing the most appropriate management for individual patients and for reducing the health resources expended on hospital admissions and parenteral antibiotics. AD can be categorized as uncomplicated or complicated, these two subtypes have a very different clinical course. The management of uncomplicated AD has become increasingly conservative, with a focus on symptomatic relief and supportive management. Recent research has brought into question the need for extended hospital admission and questioned the current use of antibiotics. Anti-inflammatory agents that reduce local inflammation in uncomplicated AD may be a useful means of reducing damage caused by inflammation and aiding earlier resolution of the inflammatory response and associated symptoms. Mesalazine is an anti-inflammatory agent that has been trialled in uncomplicated AD. Mesalazine has been shown to improve time to resolution of endoscopic and histological evidence of inflammation following an episode of AD and also reduce the rate of recurrence. In this literature review, we provide an overview of recent advances in AD classification, pathophysiology and management, and examine the possibility of introducing the use of anti-inflammatory agents in the management of uncomplicated AD.
Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents; Diverticulitis; Diverticulitis, Colonic; Hospitalization; Humans; Mesalamine
PubMed: 26211943
DOI: 10.1111/ans.13233 -
Gastroenterologia Y Hepatologia Dec 2011Aminosalycylates (5-ASA) are still the drugs of choice both for mild-to-moderate outbreaks of ulcerative colitis and to maintain long-term remission. The efficacy of... (Review)
Review
Aminosalycylates (5-ASA) are still the drugs of choice both for mild-to-moderate outbreaks of ulcerative colitis and to maintain long-term remission. The efficacy of these drugs has been widely demonstrated in placebo-controlled trials. However, when administered orally, their pharmacological characteristics hamper the desired therapeutic effect. Currently, efficiency can be optimized by exclusive or combined rectal administration. The present article reviews the available data on the efficacy of galenic preparations of 5-ASA and discusses the potential advantages of galenic forms of 5-ASA coated with a novel multi-matrix delivery system.
Topics: Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; Drug Compounding; Humans; Mesalamine; Randomized Controlled Trials as Topic; Tablets, Enteric-Coated
PubMed: 25443223
DOI: 10.1016/S0210-5705(11)70095-4 -
BMJ Case Reports Apr 2021Ulcerative colitis often develops in the reproductive age women and can cause exacerbation by pregnancy. Mesalazine (5-aminosalicylic acid) is recommended as a safe...
Ulcerative colitis often develops in the reproductive age women and can cause exacerbation by pregnancy. Mesalazine (5-aminosalicylic acid) is recommended as a safe anti-inflammatory drug during pregnancy. However, maternal mesalazine is transferred to the fetus through the placenta and may cause allergic events. A pregnant woman with severe ulcerative colitis was treated with a dose of mesalazine 4,000 mg/day from early gestation to delivery. Immediately after birth, the preterm neonate vomited bloody contents and discharged massive gross haematochezia. Serum concentrations of mesalazine and its main metabolite were high in the mother and the umbilical cord. Faecal eosinophils and drug-induced lymphocyte stimulation test suggested possibility that sensitisation with mesalazine in utero caused allergic enterocolitis like food protein-induced allergic proctocolitis. Maternal mesalazine has a potential of fetal sensitisation and cause allergic disease.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Gastrointestinal Hemorrhage; Humans; Infant, Newborn; Mesalamine; Pregnancy
PubMed: 33858883
DOI: 10.1136/bcr-2020-238743 -
Expert Review of Clinical Immunology Mar 2024Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a significant health-care burden worldwide. While medical therapy aims to induce and maintain... (Review)
Review
INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a significant health-care burden worldwide. While medical therapy aims to induce and maintain remission, optimal management of mild to moderate UC remains challenging due to heterogeneity in severity classifications and non-standardized approaches. This comprehensive review summarizes current evidence and knowledge gaps to optimize clinical decision-making in patients with mild to moderate UC.
AREAS COVERED
After an extensive literature search of PubMed, Medline, and Embase through August 2023, we provide an overview of definitions utilized to characterize mild to moderate UC severity and established therapeutic targets. Current medical treatments including mesalazine formulations, corticosteroids, and their combinations are surveyed. The role of emerging intestinal ultrasound, telemedicine, and home testing is explored. Individualized, patient-centered paradigms aiming to streamline care delivery through proactive identification of relapses are also examined.
EXPERT OPINION
Addressing inconsistencies in disease activity stratification will better align tailored regimens with each patient's profile. Advancing noninvasive technologies like ultrasound criteria and home testing could improve UC management by enabling personalized models. Realizing individualized plans through informed shared-decision making between health-care providers and fully engaged patients holds promise to maximize quality of life outcomes. Continuous improvement relies on innovation bridging different domains to overcome current limitations and push the field toward more predictive and tailored care.
Topics: Humans; Colitis, Ulcerative; Anti-Inflammatory Agents; Budesonide; Quality of Life; Mesalamine
PubMed: 38059454
DOI: 10.1080/1744666X.2023.2292768 -
Gastroenterologie Clinique Et Biologique Mar 2010We report the case of a 57-year-old woman with ulcerative colitis since eight years who developed a diffuse interstitial pneumonia linked to mesalazine (oral and...
We report the case of a 57-year-old woman with ulcerative colitis since eight years who developed a diffuse interstitial pneumonia linked to mesalazine (oral and enemas). The adverse drug-related effect to mesalazine was strongly suggested regarding improvement upon discontinuation and relapse after reinstitution of mesalazine. To date, after 8 years, the patient has not any respiratory symptom which is another argument for the adverse drug-related effect to mesalazine.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Lung Diseases, Interstitial; Mesalamine; Middle Aged; Time Factors
PubMed: 20299168
DOI: 10.1016/j.gcb.2009.08.013 -
Respiration; International Review of... 1999A 35-year-old woman with a 6-month history of ulcerative colitis and treatment with oral mesalazine (5-aminosalicylic acid) developed dry cough, low-grade fever and... (Review)
Review
A 35-year-old woman with a 6-month history of ulcerative colitis and treatment with oral mesalazine (5-aminosalicylic acid) developed dry cough, low-grade fever and bilaterally wandering pulmonary infiltrates. Improvement in clinical symptoms and radiological abnormalities occurred spontaneously after discontinuation of mesalazine. The transbronchial lung biopsy demonstrated the organizing stage of eosinophilic pneumonia. Drug lymphocyte stimulation test was positive for mesalazine and negative for sulfasalazine and sulfapyridine. The present case indicates that although mesalazine-induced eosinophilic pneumonia is an extremely rare entity, its possibility should be fully considered in patients developing unexplained respiratory symptoms while on mesalazine therapy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Lymphocyte Activation; Mesalamine; Pulmonary Eosinophilia
PubMed: 9973695
DOI: 10.1159/000029341